Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HU14.18-IL2 in Resectable Recurrent Stage III or IV Melanoma
NCT00590824Phase 2Completed
- Sponsor
- University of Wisconsin–Madison
- Start
- Dec 2007
- Primary completion
- Sep 2018
- Modality
- Immunomodulatory ADCs, Cytokines & Interferons, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Lorukafusp alfa in melanoma (2 arms), sponsored by University of Wisconsin–Madison. Primary endpoints: Ganglioside Expressed by Tumor Cells (GD2) at 1 week, Recurrence Free Survival at 24 months and 1 more. Started Dec 2007; status: completed.
02
Drugs
Lorukafusp alfa
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00590824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00590824.